Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)

This study has been completed.
Sponsor:
Collaborator:
VA Puget Sound Health Care System
Information provided by (Responsible Party):
Seattle Institute for Biomedical and Clinical Research
ClinicalTrials.gov Identifier:
NCT00990184
First received: October 2, 2009
Last updated: October 22, 2012
Last verified: October 2012
Results First Received: February 1, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Conditions: Impaired Fasting Glucose
Prediabetes
Interventions: Drug: Colesevelam
Other: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Colesevelam Hydrochloride People with IGT will take 2 weeks of placebo and then 8 weeks of study drug

Participant Flow:   Overall Study
    Colesevelam Hydrochloride  
STARTED     21  
COMPLETED     20  
NOT COMPLETED     1  
Physician Decision                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Colesevelam Hydrochloride People with IGT will take 2 weeks of placebo and then 8 weeks of study drug

Baseline Measures
    Colesevelam Hydrochloride  
Number of Participants  
[units: participants]
  21  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     15  
>=65 years     6  
Age  
[units: years]
Mean ± Standard Deviation
  60.7  ± 8.7  
Gender  
[units: participants]
 
Female     9  
Male     12  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Acute Insulin Response (AIRg) to Intravenous Glucose   [ Time Frame: Baseline and 8 weeks ]

2.  Secondary:   Insulin Sensitivity   [ Time Frame: Baseline and 8 weeks ]

3.  Secondary:   Glucose Disappearance Rate   [ Time Frame: Baseline and 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Steven E. Kahn
Organization: SIBCR
phone: 206-277-5515
e-mail: skahn@u.washington.edu


No publications provided by Seattle Institute for Biomedical and Clinical Research

Publications automatically indexed to this study:

Responsible Party: Seattle Institute for Biomedical and Clinical Research
ClinicalTrials.gov Identifier: NCT00990184     History of Changes
Other Study ID Numbers: 1.2
Study First Received: October 2, 2009
Results First Received: February 1, 2012
Last Updated: October 22, 2012
Health Authority: United States: Institutional Review Board